Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 10/20 | 0.51 |
| ▸ | MMP2 | P08253 | 7/20 | 0.51 |
| ▸ | MMP13 | P45452 | 3/20 | 0.46 |
| ▸ | MMP1 | P03956 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7201770 | 0.88 | MMP2 (0.44) | ADAM10MMP2MMP13MMP1HDAC4 | |
| SCHEMBL7204290 | 0.88 | MMP2 (0.46) | ADAM10MMP2MMP13MMP1HDAC4 | |
| SCHEMBL7201786 | 0.87 | MMP2 (0.49) | ADAM10MMP2MMP13HTR2CDRD4 | |
| SCHEMBL7201610 | 0.85 | MMP2 (0.47) | ADAM10MMP2MMP13MMP1ADAM17 | |
| SCHEMBL7206608 | 0.83 | USP5 (0.41) | ADAM10MMP2MMP13MMP1ADAM17 | |
| SCHEMBL7201577 | 0.83 | MMP1 (0.42) | ADAM10MMP2MMP13MMP1HTR2C | |
| SCHEMBL7201531 | 0.83 | MMP13 (0.57) | ADAM10MMP2MMP13MMP1 | |
| SCHEMBL7202601 | 0.82 | MMP2 (0.49) | ADAM10MMP2MMP13MMP1HTR2C | |
| SCHEMBL7205529 | 0.81 | MMP1 (0.45) | ADAM10MMP2MMP13MMP1ADAM17 | |
| SCHEMBL7205477 | 0.80 | ADAM17 (0.41) | ADAM10MMP2MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | ADAM10 254/4885MMP2 13/4885MMP13 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.